Effect of anti-TNF drugs on HAQ-PS and cost percentage achieving HAQ-PS MCID over 3 years in RA, PsA, and AS.
| All Patients, mean (SE) | RA, mean (SE) | PsA, mean (SE) | AS, mean (SE) | p | |
|---|---|---|---|---|---|
| Baseline | |||||
| n | 255 | 175 | 51 | 29 | |
| HAQ-PS | 1.85 (0.04) | 1.91 (0.06) | 1.79 (0.09) | 1.84 (1.12) | 0.8671 |
| Year 1 | |||||
| n | 211 | 145 | 46 | 20 | |
| Δ HAQ-PS | −0.55 (0.07) | −0.57 (0.07) | −0.44 (0.18) | −0.66 (0.20) | 0.7323 |
| % HAQ-PS ≥ 0.3 | 62.3 (3.60) | 62.3 (4.41) | 60.5 (7.54) | 66.7 (11.4) | |
| NNT* | 1.61 | 1.61 | 1.65 | 1.50 | |
| Cost, $* | 34,201 | 43,201 | 35,051 | 31,866 | |
| Year 2 | |||||
| n | 127 | 91 | 28 | 8 | |
| Δ HAQ-PS | −0.58 (0.09) | −0.60 (0.11) | −0.65 (0.17) | −0.50 (0.35) | 0.2842 |
| % HAQ-PS ≥ 0.3 | 62.0 (4.69) | 62.2 (5.68) | 63.0 (9.47) | 57.1 (20.2) | |
| NNT* | 1.61 | 1.61 | 1.59 | 1.75 | |
| Cost, $* | 34,919 | 34,919 | 34,486 | 37,955 | |
| Year 3 | |||||
| n | 79 | 56 | 18 | ||
| Δ HAQ-PS | −0.55 (0.11) | −0.56 (0.13) | −0.67 (0.23) | 0.1463 | |
| % HAQ-PS ≥ 0.3 | 53.9 (5.76) | 63.8 (7.08) | 55.6 (12.1) | ||
| NNT* | 1.86 | 1.57 | 1.80 | ||
↵* For percentage of HAQ-PS ≥ 0.3. TNF: tumor necrosis factor; HAQ-PS: Health Assessment Questionnaire Pain Score; MCID: minimal clinically important difference; RA: rheumatoid arthritis; PsA: psoriatic arthritis; AS: ankylosing spondylitis; SE: standard error: NNT: number needed to treat.